These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1467 related items for PubMed ID: 18971320

  • 1. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S, Robey RW, Bates SE, Ambudkar SV.
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [Abstract] [Full Text] [Related]

  • 2. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene.
    Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y.
    Cancer Sci; 2010 Jun 28; 101(6):1493-500. PubMed ID: 20345483
    [Abstract] [Full Text] [Related]

  • 4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.
    Cancer Res; 2008 Oct 01; 68(19):7905-14. PubMed ID: 18829547
    [Abstract] [Full Text] [Related]

  • 5. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K.
    Eur J Pharmacol; 2015 Jan 05; 746():258-66. PubMed ID: 25455500
    [Abstract] [Full Text] [Related]

  • 6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY, Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS, Trombetta LD.
    Cancer Lett; 2018 May 01; 421():186-198. PubMed ID: 29331420
    [Abstract] [Full Text] [Related]

  • 7. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R, Chen ZS.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):189-99. PubMed ID: 23673445
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.
    Drug Metab Dispos; 2010 Aug 01; 38(8):1371-80. PubMed ID: 20423956
    [Abstract] [Full Text] [Related]

  • 9. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 10. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.
    Biochem Pharmacol; 2013 Feb 15; 85(4):514-24. PubMed ID: 23261525
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 15; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 12. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV.
    Mol Cell Biochem; 2007 Feb 15; 296(1-2):85-95. PubMed ID: 16960658
    [Abstract] [Full Text] [Related]

  • 13. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
    Eadie LN, Saunders VA, Hughes TP, White DL.
    Leuk Lymphoma; 2013 Mar 15; 54(3):569-78. PubMed ID: 22845311
    [Abstract] [Full Text] [Related]

  • 14. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP, Hsiao SH, Sim HM, Luo SY, Tuo WC, Cheng HW, Li YQ, Huang YH, Ambudkar SV.
    Biochem Pharmacol; 2013 Oct 01; 86(7):904-13. PubMed ID: 23962445
    [Abstract] [Full Text] [Related]

  • 15. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
    Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR.
    PLoS One; 2013 Oct 01; 8(8):e71266. PubMed ID: 23967177
    [Abstract] [Full Text] [Related]

  • 16. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.
    Cancer Res; 2011 Apr 15; 71(8):3029-41. PubMed ID: 21402712
    [Abstract] [Full Text] [Related]

  • 17. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
    Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV, Chen ZS.
    Biochem Pharmacol; 2009 Mar 01; 77(5):781-93. PubMed ID: 19059384
    [Abstract] [Full Text] [Related]

  • 18. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
    Michaelis M, Rothweiler F, Nerreter T, Sharifi M, Ghafourian T, Cinatl J.
    J Pharm Pharm Sci; 2014 Mar 01; 17(1):92-105. PubMed ID: 24735762
    [Abstract] [Full Text] [Related]

  • 19. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C, Ozvegy-Laczka C, Apáti A, Magócsi M, Német K, Orfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B.
    Br J Pharmacol; 2009 Oct 01; 158(4):1153-64. PubMed ID: 19785662
    [Abstract] [Full Text] [Related]

  • 20. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.